Stockwinners Market Radar for May 10, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:59 EDT Tiptree files to delay Form 10-Q - In a regulatory filing, Tiptree said it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 by May 10, 2017, the original due date for such filing.

18:56 EDT Actinium Pharmaceuticals files to delay Form 10-Q - According to a regulatory filing, Actinium Pharmaceuticals said it is delaying the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2017 because the company needs additional time to complete its disclosure for such period. The company has not concluded its review and analysis of transactions necessary for the closing of its books for the quarter. Because the review and analysis is ongoing, the company can provide no assurances that it will be able to file the Form 10-Q by May 15, 2017, the expiration of the 5-day extension period provided in Rule 12b-25b.

18:19 EDT On The Fly: After Hours Movers - UP AFTER EARNINGS: Real Industry (RELY), up 26.5%... Pegasystems (PEGA), up 10.4%... Whole Foods (WFM), up 3.1%... Intrexon (XON), up 2.8%... DryShips (DRYS), up 1.1%... Energous (WATT), up 1%... Omeros (OMER), up 1%. ALSO HIGHER: Sangamo (SGMO), up 41.4% after it announced a collaboration with Pfizer (PFE) for a hemophilia A gene therapy... Merck (MRK), up 3.2% after it said that the FDA approved Keytruda as a first-line combination therapy in NSCLC... O'Reilly Automotive (ORLY), up 1% after it increased the authorization amount under its share repurchase program by an additional $1B, raising the aggregate authorization under the program to $8.75B... U.S. Steel (X), up 0.6% after it announced the retirement of chief executive officer Mario Longhi. DOWN AFTER EARNINGS: NantHealth (NH), down 24.4%... Snap (SNAP), down 23.5%... MannKind (MNKD), down 22.5%... Aviat Networks (AVNW), down 16%... Papa Murphy's (FRSH), down 11.8%... Neovasc (NVCN), down 7.9%... Symantec (SYMC), down 7.2%... e.l.f. Beauty (ELF), down 4.7%... 21st Century Fox (FOXA), down 1.4%. ALSO LOWER: Conatus (CNAT), down 15.2% after it initiated an offering of 4.8M shares... New York REIT (NYRT), down 10% after it said that the net assets in liquidation at March 31, 2017 would result in liquidating distributions of roughly $9.25 per common share... Arbor Realty (ABR), down 5.6% after it filed to sell 9.5M shares of common stock... Bristol-Myers (BMY), down 2.1% after Merck announced FDA's approval of Keytruda as a first-line combination therapy... Bright Horizons (BFAM), down 0.5% after it filed to sell 4.15M shares for holders.

18:04 EDT Ctrip.com reports Q1 gross margin 80% - Improving from 73% in the same quarter of 2016 and 78% in the previous quarter, due to further efficiency gain. Operating margin for the first quarter of 2017 was 7%. Excluding share-based compensation charges, Non-GAAP operating margin for the first quarter of 2017 was 15%, improving significantly from 0% in the same quarter a year ago, driven mainly by improvements in operating efficiency across the board and synergies from the invested companies.

17:33 EDT Whole Foods boosts dividend by 29%, authorizes new $1.25B repurchase - Whole Foods' Board of Directors announced a new capital allocation strategy that reflects confidence in the Company's future growth and cash flow generation, while expanding its commitment to return capital to shareholders. As part of this strategy, the Board announced a 29% increase in the regular quarterly dividend to 18c per share and authorized a new $1.25B share repurchase program, with the intent to opportunistically utilize the authorization over the next 18 months. The new authorization will replace the Company's existing program. The next quarterly dividend to be declared is expected to be payable on July 11 to shareholders of record as of June 30.

17:30 EDT Whole Foods CEO: 'Accelerating path to enhanced value creation' - "We are accelerating our path to enhanced value creation to deliver better returns for our shareholders," said John Mackey, co-founder and CEO of Whole Foods Market. "Today's announcement is a powerful combination of accelerated initiatives and new cost savings with clear timelines to deliver. We are on a path to return to positive comparable store sales and earnings growth next year. Our increased dividend and new share repurchase authorization demonstrate our Board's confidence in our long-term growth strategy and continued ability to generate strong cash flow. The Board will continue its comprehensive review of all opportunities to create value. We look forward to continuing our dialogue with shareholders and providing future updates on our progress."

17:27 EDT Whole Foods announces board refreshment - Whole Foods Market announced a significant refreshment of its Board of Directors by appointing five new independent directors, effective immediately: Ken Hicks; Joe Mansueto; Sharon McCollam; Scott Powers; and Ron Shaich. The Company also announced that Gabrielle Sulzberger has been appointed the new Chair of the Whole Foods Market Board of Directors and Mary Ellen Coe has been appointed the new Chair of the Nominating & Governance Committee.Gabrielle Sulzberger has served as an independent director of the Company since 2003. Ms. Sulzberger's years serving on public company boards and experience as a chief financial officer provide Whole Foods Market with financial, M&A and risk assessment expertise. Most recently and since December 2016, Ms. Sulzberger served as Chair of the Nominating & Governance Committee of the Whole Foods Market Board. Mary Ellen Coe joined the Whole Foods Market Board of Directors in November 2016 and has served on the Nominating & Governance Committee and has assisted Ms. Sulzberger throughout the Board refreshment process. As an executive at Google, Ms. Coe brings deep technology expertise in marketing, digital strategy and brand strategy.

17:12 EDT Ocwen files for delayed 10-Q - Ocwen filed to delay its 10-Q quarterly regulatory filing, stating that it "requires additional time to complete its financial closing procedures and ensure appropriate disclosure of various recent events impacting the company... The company currently expects to file its 10-Q on or before May 15, the prescribed due date pursuant to this Form 12b-25."

17:07 EDT Snap says Spectacles sold 'little over' $8M in Q1

17:00 EDT Omeros says Novartis unit gives notice of generic Omidria filing - Omeros (OMER) stated in its 10-Q quarterly filing: "On May 10, we received a notice letter from [Novartis (NVS) unit] Sandoz that Sandoz has filed an ANDA containing a Paragraph IV Certification under the Hatch-Waxman Act seeking approval from the FDA to market a generic version of OMIDRIA prior to the expiration of six Orange Book-listed patents covering OMIDRIA. These patents were granted following review by the U.S. Patent and Trademark Office, are presumed to be valid under governing law, and can only be invalidated in federal court with clear and convincing evidence. We are currently reviewing the details of Sandoz's notice letter. Omeros is confident in its intellectual property and intends to vigorously enforce its patent rights."

16:48 EDT Cabot raises quarterly dividend 5% to 31.5c per share - The board of directors of Cabot Corporation announced a quarterly dividend on the company's common stock of 31.5c per share payable on June 9, 2017 to shareholders of record at the close of business on May 26, 2017. This represents a 5% increase from the previous dividend.

16:47 EDT Tronox CEO Tom Casey retiring, Peter Johnston named Interim CEO - Tronox CEO Tom Casey will retire from his position for health reasons, effective May 15. Casey will remain as chairman of the board, where he will support the management transition and oversee the transaction processes for the acquisition of Cristal Chemicals' titanium dioxide assets, the marketing of the Tronox Alkali business, and related matters. The company has begun the implementation of the executive leadership transition plan previously announced by the board of directors on March 29. Peter Johnston, formerly head of Glencore Corporation's global nickel business and CEO of Minara Resources, will assume the role of interim CEO during the period in which the company identifies a successor to Casey. Johnston has been a director of the company since August 1, 2012 and will continue to serve as a director of the company. The board has retained Korn Ferry to conduct the CEO search and will consider both internal and external candidates.

16:46 EDT Snap CFO: Revenue growth driven by 'strong' advertiser demand

16:44 EDT Snap strategy chief: Users spent 30-plus minutes with Snapchat per day in Q1

16:43 EDT Silver Wheaton changing name to Wheaton Precious Metals Corp. - Silver Wheaton shareholders approved the change of name of Silver Wheaton Corp. to Wheaton Precious Metals Corp. with 98% of the votes cast in favour.

16:41 EDT Abercrombie & Fitch confirms preliminary discussions for potential transaction - Abercrombie & Fitch Co. reported that, after receiving expressions of interest, it is in preliminary discussions with several parties regarding a potential transaction with the company. There can be no assurance these discussions will lead to a definitive agreement or that a transaction will be consummated. The company does not intend to make any further comments on the discussions until they are concluded.

16:40 EDT Snap CEO: Android accounted for over 30% of Q1 net adds - Snap executives are speaking on the company's Q1 earnings conference call.

16:39 EDT Copa Holdings reports Q1 on-time performance of 89.1% - Copa Airlines reported consolidated on-time performance of 89.1% and a flight-completion factor of 99.9% for 1Q17, maintaining its position among the best in the industry.

16:38 EDT O'Reilly Automotive announces additional $1B share repurchase authorization - O'Reilly Automotive announced that its board approved a resolution to increase the authorization amount under its share repurchase program by an additional $1B, raising the aggregate authorization under the program to $8.75B. The additional $1B authorization is effective for a three-year period, beginning on May 10.

16:35 EDT Fidelity National receives Private Letter Ruling from IRS - Fidelity National Financial has received a Private Letter Ruling from the IRS related to the previously announced tax-free plan whereby it intends to distribute all 83.3 million shares of Black Knight Financial (BKFS) common stock that it currently owns to FNF Group (FNF) shareholders, and to redeem all FNFV Group (FNFV) tracking stock shares in exchange for shares of common stock of Cannae Holdings, a newly formed, publicly-traded company that will hold the assets of FNFV. The trading symbol 'CNNE' is on hold with the NYE. Following the distributions, FNF, Cannae Holdings and Black Knight will each be independent, fully-distributed, publicly-traded common stocks, with FNF and FNFV/Cannae Holdings no longer being tracking stocks. The closing of the tax-free distributions is expected in Q3.

16:33 EDT Gate City Capital reports 6.65% passive stake in AMREP

16:31 EDT CNO Financial approves additional $300M for repurchase program - CNO Financial has approved an additional $300M to repurchase the company's outstanding common stock. As of March 31, CNO had repurchased $43.0M of common stock in 2017 and had remaining repurchase capacity under the buyback program of approximately $210M. In addition, CNO shareholders elected nine directors to serve terms expiring at next year's annual meeting, approved the Amended and Restated Long-Term Incentive Plan, ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for 2017

16:30 EDT Snap reports Q1 R&D spend $806M vs. $28M last year - Reports Q1 sales and marketing spend $220M vs. $15M last year.

16:30 EDT Sangamo trading resumes

16:25 EDT TechTarget announces strategic partnership with HG Data - TechTarget and HG Data, a specialist in B2B market intelligence for sales, marketing and analytics, announced a strategic partnership to deliver technology install information directly within TechTarget's Priority Engine purchase intent insight platform. "The first offering of its kind in the market, the data integration will allow marketing and sales teams to access install base information and activity-based data at both the account and contact level in the same platform," the companies said.

16:20 EDT TransEnterix sees funding operations into 2Q18

16:20 EDT Centennial raises its 2020 oil production target by 20% - Centennial raised its 2020 oil production target by 20% to 60,000 barrels per day in connection with the GMT acquisition.

16:15 EDT Whole Foods appoints Keith Manbeck as new CFO - Whole Foods Market announced the appointment of five new independent directors and named Gabrielle Sulzberger the new chair of the board, and Mary Ellen Coe the new chair of the nominating & governance committee. The company also announced the appointment of Keith Manbeck as its new Chief Financial Officer.

16:14 EDT TechTarget reauthorizes stock buyback - TechTarget said its board of directors has reauthorized the common stock repurchase program to allow the company to use the remaining balance of the unused authorization under the 2016 Repurchase Program after its original expiration in June 2017. The reauthorized program has no time limit and may be suspended at any time. In general, the company utilizes 10b5-1 trading plans to purchase the shares on the open market.

16:10 EDT Synacor says 'remain well positioned' for 2019 targets - The company said, "In April, we strengthened our balance sheet with $20 million in capital from an equity offering in order to execute on our strong growth pipeline. We remain well positioned to deliver on our target of $300 million in revenue and $30 million in adjusted EBITDA in 2019."

16:10 EDT Neovasc announces "substantial doubt" about continuing as going concern - Neovasc reported in its earnings release that it may be faced with significant monetary damages in the litigation with CardiAQ that could exceed its resources and/or the loss of intellectual property rights that could have a material adverse effect on the company and its financial condition. These circumstances indicate the existence of material uncertainty and cast substantial doubt about the company's ability to continue as a going concern.

16:08 EDT Inseego says closes $20M financing transaction - Inseego and certain of its direct and indirect subsidiaries entered into a Credit Agreement with Lakestar Semi, a private investment fund managed by Soros Fund Management, on May 8. Pursuant to the Credit Agreement, the Lender provided the Company with a term loan in the principal amount of $20M with a maturity date of May 8. "I am very pleased to announce this funding, which provides Inseego with the necessary financing to pursue our near-term objectives, including the sale of the MiFi business and investing in our growing Ctrack and Inseego North America businesses," said Sue Swenson, Chief Executive Officer. In addition, upon entering into the Credit Agreement described above, the Company terminated its revolving credit facility with Wells Fargo Bank dated as of October 31, 2014. The Prior Credit Agreement provided for a $10M secured revolving credit facility.

16:06 EDT U.S. Steel announces retirement of CEO Mario Longhi - United States Steel announced the retirement of Mario Longhi from the company on June 30, 2017. He stepped down as CEO on May 8, but he will remain on the board of directors and serve as an employee of the company, providing transitional support, until his retirement. Also, on May 8, David B. Burritt, currently president and COO, was elected by the board of directors to assume the position of president and CEO as well as become a member of the board.

16:05 EDT Collegium Pharmaceutical says funded into 2019 - Based on the company's current operating plans, it believes that its existing cash resources, together with expected cash inflows from the commercialization of Xtampza ER will fund its operating expenses, debt service and capital expenditure requirements into 2019.

16:01 EDT Inseego CFO Michael Newman resigns - Inseego announced that Michael Newman, Chief Financial Officer, has decided to resign from his position effective May 15, 2017 for family and personal reasons. He will serve in an advisory role to assist in the conclusion of the company's sale of its MiFi business and the transition to a new permanent CFO. Newman will be replaced by Interim CFO Tom Allen. Allen previously served as Interim CFO for Inseego's predecessor company, Novatel Wireless, from June 2014 to September 2014, when Mr. Allen transitioned the CFO role to Newman. Inseego will undertake a comprehensive search for a permanent CFO.

15:28 EDT Pingtan Marine 'aware' of financial blog's allegations - Pingtan Marine Enterprise said it is aware of allegations posted in a financial blog today. "Pingtan is committed to conducting its business and operations in an ethical manner, and in compliance with applicable laws," the company said. 'The company is looking into the allegations and intends to make information publicly available as appropriate."

15:10 EDT Triumph Group falls after Boeing halts 737 MAX flights for engine inspections - Triumph Composite Systems (TGI) supplies approximately 65% of Boeing's (BA) composite ducting and is currently the OEM manufacturer for all Boeing commercial aircraft floor panels. Shares of Triumph Group which were trading lower the entire day, hit a session low of $21.23 on news that Boeing was halting 737 MAX flights for engine inspections. Shares of Triumph Group are currently down 9.9% to $21.90 per share in late afternoon trading.

14:58 EDT Calpine trading halted, volatility trading pause

14:44 EDT GE falls after Boeing halts 737 MAX flights for engine inspections - GE (GE) supplies engines for the 737 MAX through CFM International. Shares of General Electric hit an intraday low of $28.60 per share on the Boeing (BA) news. Shares of GE are down almost 1% to $28.68 per share in afternoon trading.

14:35 EDT Boeing drops after halting Max flights for engine issue - Shares of Boeing (BA) dropped after the company announced the suspension of 737 Max flights due to a manufacturing issue with low-pressure turbine discs. Engine supplier CFM International, a joint venture between General Electric (GE) and Safran (SAFRY), notified Boeing of the manufacturing issue, Boeing said in a statement. The 737 Max remains in testing and is yet to commence commercial flights. Shares of plane suppliers Spirit AeroSystems (SPR), Textron (TXT), United Technologies (UTX) and Rockwell Collins (COL) followed Boeing lower on the news. Boeing in afternoon trading is down $2.59 to $182.90.

14:26 EDT Rockwell Collins, Spirit AeroSystems drop after Boeing halts Max flights

14:24 EDT Boeing drops 2% to $182.08 after suspending 737 Max flights on engine issue

14:08 EDT Quaker Chemical raises quarterly dividend 3% to 35.5c per share - The board of Quaker Chemical declared a 35.5c per share quarterly dividend, a 3% increase compared to the quarterly dividends declared over the past four quarters. The quarterly dividend is payable on July 31 to shareholders of record at the close of business on July 17. "Our strong cash flow generation and our confidence in the future earnings of the company allow us to continue our consistent dividend payout and support this increase, while striking a balance with the expected future demands on cash from our Houghton combination," the company said.

14:01 EDT Nvidia unveils 'NVIDIA GPU Cloud' - NVIDIA announced the NVIDIA GPU Cloud, "a cloud-based platform that will give developers convenient access -- via their PC, NVIDIA DGX system or the cloud -- to a comprehensive software suite for harnessing the transformative powers of AI." The company explained that "harnessing deep learning presents two challenges for developers and data scientists. One is the need to gather into a single stack the requisite software components -- including deep learning frameworks, libraries, operating system and drivers. Another is getting access to the latest GPU computing resources to train a neural network. NVIDIA solved the first challenge earlier this year by combining the key software elements within the NVIDIA DGX-1 AI supercomputer into a containerized package. As part of the NGC, this package, called the NGC Software Stack, will be more widely available and kept updated and optimized for maximum performance. To address the hardware challenge, NGC will give developers the flexibility to run the NGC Software Stack on a PC, on a DGX system or from the cloud." NGC is expected to enter public beta by the third quarter. Pricing will be announced at a later date. Separately, the company also announced a new lineup of NVIDIA DGX AI supercomputers, delivering "groundbreaking AI computing power three times faster than the prior DGX generation, providing the performance of up to 800 CPUs in a single system."

13:49 EDT Microsoft confirms Windows 10 being used on 500M devices - During his opening keynote, Microsoft CEO Satya Nadella announced that Windows had reached 500 million Windows 10 monthly active devices and noted how - together - Windows, Microsoft Office and Microsoft Azure offer developers more than a billion opportunities to connect their innovations with Microsoft customers. Microsoft also announced new Azure data and cloud services to help developers quickly modernize their existing apps, new AI and Azure services that allow any developer to more easily build intelligent apps, with understanding and natural user interaction capabilities, and showcased new data, IoT edge and AI services built for a future with an intelligent cloud and intelligent edge. Microsoft showcased how it is meeting developers where they are, and helping them be more successful, with new Microsoft Azure and Visual Studio services and tools to help modernize existing applications and quickly build intelligent apps for all major platforms: Introducing Azure Cosmos DB, the industry's first globally distributed, multimodel database service to deliver horizontal scale with guaranteed uptime, throughput, consistency and single-digit millisecond latency at the 99th percentile. New MySQL- and PostgreSQL-managed services that join Azure SQL Database. Azure SQL Database improvements. General availability of Visual Studio 2017 for Mac. With more than 100 million monthly commercial active users, Office 365 is where the world works. Today Microsoft announced plans to better connect developers with Office 365 customers around the globe.

13:38 EDT Wendy's CEO: No impact from recent McDonald's fresh beef test - Speaking during the company's Q1 earnings conference call earlier, Wendy's (WEN) CEO Todd Penegor appeared to downplay a recent "fresh beef" test by McDonald's (MCD). Asked by Wall Street analysts about any potential impact from the McDonald's fresh beef test in Dallas -- or whether it may in fact have raised awareness for Wendy's consistent message of freshness -- Penegor stated: "As we looked at where they were testing -- we're very conscious of what they were doing -- we didn't see material impacts to our business when that message was coming out. And as you know, as they came out with their announcement, we had some fun in the social landscape and social media with that announcement because it does create more awareness, and it does create some credibility to what we've been saying for almost 48 years: Fresh, never-frozen North American beef tastes better, and the consumer prefers it. And they must be seeing the same thing if that's where they need to go. But remember, they're not -- they're talking about it in the future; sometime in the middle of next year on just one of their hamburger lines." The CEO also noted that the company will "continue to leverage that point of differentiation for a long time to come."

13:29 EDT Franklin Resources reports 13.2% passive stake in DelMar Pharmaceuticals

13:18 EDT adidas sells TaylorMade, other golf brands for $425M - adidas announced that it has entered into a definitive agreement to sell its TaylorMade, Adams Golf and Ashworth golf brands to a newly formed affiliate of KPS Capital Partners for a total consideration of $425M, around half of which will be paid in cash with the remainder in a combination of secured note and contingent considerations. The transaction, which is subject to customary closing conditions, is expected to be completed later in 2017. As a result of the transaction, adidas will record a non-operational negative P&L impact in the high-double-digit to low-triple-digit million euro range, which will be reported in discontinued operations as part of the company's 2017 results.

12:47 EDT NxStage Medical announces FDA clearance for new hemodialysis system - NxStage Medical announced that its next generation hemodialysis system has received FDA clearance. This system consists of new features and capabilities, including a new touchscreen user interface and integrated blood pressure monitor designed to enhance ease of use for patients performing home hemodialysis.

12:41 EDT Left sees 'wonderful opportunity' to short Wayfair after rally - Citron Research's Andrew Left is speaking on CNBC.

12:24 EDT Time Warner launches TBS, TNT apps on Google Chromecast, Roku - Time Warner (TWX) said in a statement: "Four years after becoming the first national entertainment networks to stream on-air content live, Turner's TBS & TNT are once again leading the industry in reimagining the television viewing experience. Through an extensive multiplatform initiative, the two networks have begun issuing major updates to their streaming apps for iOS, Apple (AAPL)TV, Android, and Amazon Fire (AMZN), as well as to the tbs.com and tntdrama.com websites In addition, TBS & TNT are expanding their digital footprint to new platforms with app launches available today on Roku devices and Google Chromecast (GOOG), as well as on VIZIO SmartCast devices. The networks will also launch their immersive app experiences on other g ame consoles and connected televisions later this year." Reference Link

12:16 EDT Cardiovascular Systems up 4% after CTFN says up for sale - Shares of Cardiovascular Systems jumped after CTFN reported that the company is up for sale. Shares are up 4% to $31.26.

12:01 EDT Ackman teases two potential 'traditional' activist positions - Bill Ackman said on today's quarterly call that Pershing Square is working on two "traditional" activist positions. The potential companies are "simple, free cash flow generative businesses," Ackman said. He added that Pershing is yet to complete the due diligence and has not bought shares of either company. Ackman on the call also discussed Pershing's short position in Herbalife (HLF), long position in Chipotle (CMG), as well as Fannie Mae (FNMA) and Freddie Mac (FMCC).

11:47 EDT Pershing's Ackman says Herbalife earnings fundamentals are deteriorating - Bill Ackman, speaking on Pershing Square's quarterly conference call, said Herbalife's (HLF) earnings fundamentals are deteriorating. Ackman added that the Fannie Mae (FNMA), Freddie Mac (FMCC) litigation is likely to take years and that Chipotle's (CMG) new board is working well.

11:36 EDT Clearbridge Investments reports 10.12% passive stake in Ardagh Group

11:26 EDT Battleground: Analysts diverge on Yelp after earnings, weaker outlook - Shares of Yelp (YELP) are sliding after the online review company reported slower than expected revenue growth and slashed guidance. While research firms MKM Partners and RBC Capital moved to the sidelines following the announcement, Wells Fargo and Goldman Sachs upped their ratings for Yelp. RESULTS: Tuesday night, Yelp reported first quarter adjusted earnings per share of 19c, which was better than the expected loss of (8c), and revenue of $197.3M, falling short of consensus estimates. The company also cut its 2017 revenue view to $850M-$865M and its 2017 adjusted EBITDA forecast to $130M-$145M. Additionally, Yelp said it sees second quarter revenue of $202M-$206M, with consensus at $215.42M. MOVING TO THE SIDELINES: In a post-earnings research note, MKM Partners analyst Rob Sanderson downgraded Yelp to Neutral from Buy and lowered his price target on the shares to $27 from $48, citing sales execution issues. The analyst noted that while management believes issues have been addressed, he expects investors will be skeptical until consistency is established and this will take multiple quarters. In the meantime, the stock is likely to overshoot on the downside in the near-term, he argued. His peer at RBC Capital voiced a similar opinion, cutting his rating for Yelp to Sector Perform from Outperform due to execution and value proposition problems highlighted by the second consecutive quarter of Advertising Account issues. Analyst Mark Mahaney believes the value proposition of the Yelp platform for Advertisers can be improved and better communicated, but it will take time. The analyst also lowered his price target on the shares to $27 from $49. REMAIN BULLISH: Conversely, Goldman Sachs analyst Heath Terry upgraded Yelp to Buy from Neutral as he believes the first quarter advertiser issues are fully reflected at these levels and sees potential for upside to revised estimates, particularly if the company can build on the re-acceleration in user growth seen in first quarter. While Yelp faces considerable competition from the larger internet and mobile platforms, at current levels with traffic and transactional revenue growing the analyst believes the risk/reward is favorable. Nonetheless, Terry lowered his price target on the shares to $34 from $42. This morning, Wells Fargo analyst Peter Stabler also upgraded Yelp to Market Perform from Underperform, citing valuation. Additionally, the analyst said that although specific drivers remain cloudy, management pointed to retention challenges as impacting expected remainder of year growth rates. He lowered his price target on the shares to $27 from $30. PRICE ACTION: In late morning trading, shares of Yelp have dropped over 16% to $29.08.

11:21 EDT Vulcan Materials says should see accelerated growth in 2H

11:14 EDT Vulcan Materials says acquisitions reflect confidence in market conditions

11:12 EDT Vulcan Materials says private demand in California improving - Comments from Q1 earnings conference call.

11:04 EDT Meredith announces new licensing agreement with FGX International - Meredith announced that it has entered a licensing agreement with FGX International, the owner and designer of Foster Grant eyewear, to produce a line of sunglasses for the SHAPE brand. The two industry leaders partnered to create a co-branded product: Foster Grant for SHAPE.

10:53 EDT Ionis down after FDA posts Warning Letter sent to trial sponsor - The move lower in shares of Ionis Pharmaceuticals is being an FDA Warning Letter, dated March 20, 2017, sent to Merrill Benson of Indiana University. The Warning Letter informs Benson of "objectionable conditions" observed during the agency's inspection conducted at a clinical site between October 11, 2016, and November 10, 2016. Benson is conducting investigator-sponsored, open-label studys with Ionis' IONIS-TTRR. Shares of Ionis are down 3% to $45.45 in morning trading. Reference Link

10:44 EDT Pingtan halted again for volatility after dropping 25% to $3.10

10:38 EDT Pingtan Marine Enterprise halted for volatility after dropping 16% to $3.45

10:32 EDT NAO Executive Chairman Herbjorn Hansson, family increase stake in NAO to 5.4% - A company owned by the NAO Executive Chairman, Herbjorn Hansson and his son, Alexander, bought 500,000 shares in NAO at an average price of $1.18 per share. Also yesterday they bought 500,000 NAO shares. The appropriate filing will be undertaken as the Hansson family now holds shares equivalent to 5.4% of NAO.

10:22 EDT CVS Health investors elect former SEC Chairman Mary Schapiro as director - Shareholders of CVS Health re-elected all eleven standing members of the CVS Health Board of Directors and voted to elect the Honorable Mary L. Schapiro, the 29th chairman of the U.S. SEC, as a new member of the company's Board today during the company's Annual Meeting of Stockholders.

10:03 EDT BAE Systems selected by Treasury Department to support TFI - The U.S. Department of Treasury has selected BAE Systems to support the agency's Office of Terrorism and Financial Intelligence in safeguarding the country's financial system against threats posed by rogue nations, terrorist facilitators, drug cartels, and other national security threats. BAE Systems is among a group of federally-approved contractors that will have the opportunity to compete for future task order contracts to assist TFI in researching, analyzing, and documenting complex financial, trade, and other business activities in support of federal investigations and prosecutions. The maximum lifecycle value of all task orders to be awarded under the contract is estimated at $135M. This work plays a critical role in enforcing the violations and sanctions programs administered by the Department of Treasury.

10:01 EDT 3M to sell automated license/number plate recognition business to Neology - 3M announced that it has entered into agreements to sell its tolling and automated license/number plate recognition business, which is part of 3M's Traffic Safety and Security Division, to Neology, a leading provider of integrated solutions for tolling, electronic vehicle registration and public safety applications. Neology is a subsidiary of SMARTRAC, a portfolio company managed by One Equity Partners, a middle-market private equity firm. 3M's tolling and automated license/number plate recognition business is a provider of tolling and automated license/number plate recognition solutions. Its tolling solutions include RFID readers and tags, automatic vehicle classification systems, lane controller and host software, and back office software and services. It also provides mobile and fixed cameras, software, and services in automated license/number plate recognition. The business has annual global sales of approximately $40M. The transaction is expected to close by the third quarter of 2017, and is subject to customary closing conditions, regulatory approvals and consultation or information requirements with relevant works councils. Approximately 85 employees are expected to join Neology upon completion of the sale.

09:56 EDT Neonode shareholder urges board to hire banker to explore alternatives - "Gentlemen - In furtherance of the conference call this morning, and first quarter results, I want to strongly urge the Board to hire an investment banker to explore all strategic alternatives. I believe, as was discussed on the call, that there are significant opportunities for Neonode's various products and technology. However, the shareholders have heard the same story for a long period of time in which management has consistently over-promised and under-delivered. It should be obvious that management should be vigilant with regard to controllable expenses, including all compensation costs. Cash/working capital must be protected. To take full advantage of the opportunities that you have, Neonode should be part of a company that has the balance sheet to support the significant new product offerings that you have. In addition, it's clear that Neonode would benefit from additional expertise in retail marketing for Airbar. I will be talking with other shareholders, and I personally expect that you will respond to this promptly by doing the right thing for your shareholders. Sincerely, Ronald L. Chez."

09:43 EDT NXP Semiconductors awarded OSCCA certificate from China - NXP Semiconductors announced that the China Office of State Commercial Cryptography Administration awarded it with a certificate to become a designated producer of commercial cipher products. This certificate marks NXP as the first, and currently only, approved foreign-based semiconductor company to be awarded authorization to develop and produce certified cryptography products in China.

09:32 EDT UPS Express Critical service launches in Europe - UPS Express Critical service launched in Europe for urgent, time-critical shipments that require special handling such as aircraft parts or surgical tools. Such services are vital to the healthcare, manufacturing and aerospace sectors when speed of delivery matters most, UPS said.

09:23 EDT TCW proposes to become external asset manager for Hercules Capital - The TCW Group announced that it has filed a preliminary proxy statement with the U.S. SEC, which includes TCW's proposal to become the external asset manager for Hercules Capital. TCW previously sent the terms of its proposal to Hercules' Independent Directors on May 6, 2017, three days after Hercules filed with the SEC preliminary proxy materials regarding its proposal to externalize Hercules' investment management function by transferring it to Hamilton Advisers LLC, a newly formed entity owned by Hercules' co-founder, chairman, president and CEO, Manuel A. Henriquez. On May 9, 2017, Hercules' counsel transmitted a letter on behalf of the independent members of the Board stating that the independent board members "take [the TCW] proposal seriously and will evaluate it and respond to [TCW] in a timely manner." "We made a good faith request to the Hercules independent board members to delay the Special Meeting scheduled in June so they could engage with us in substantive discussions and thoroughly evaluate our proposal, which we believe is a superior proposal that is in the best interests of Hercules' stockholders," said Jess Ravich, Group Managing Director and Head of Alternative Products at TCW. "We still welcome the opportunity to engage with the Hercules Board, but their failure to provide any time frame for a meaningful response left us with no choice but to file preliminary proxy materials, as we otherwise would not have sufficient time to make our case to the Hercules stockholders ahead of the Special Meeting. Ultimately, we believe TCW will create more value for Hercules' stockholders over both the short- and long-term, and we look forward to presenting the merits and greater value of our proposal in more detail over the coming weeks." Whereas the current proposal by Hercules' management is inherently uncertain and contemplates extensive ramp-up costs, TCW's proposal would immediately provide superior economics and competitive advantages in the form of economies of scale, employee compensation and asset diversification, in order to create more value for stockholders.

09:20 EDT Time Inc. says open to JVs with some of its brands

09:10 EDT Richmond Brothers, Ravich respond to Rockwell Q1 earnings - Investment advisor Richmond Brothers and Mark Ravich, who together with their affiliates beneficially own over 6.1M shares, or 11.8% of the company's outstanding common stock, today commented on Rockwell's Q1 results announcement. David Richmond, chairman of Richmond Brothers, and Ravich issued the following statement: "Unfortunately for shareholders, Rockwell failed to provide any meaningful, substantive updates on yesterday's earnings call. The sad story of Rockwell's underperformance remains the same: little revenue, continued losses, in this case, 9c per share for Q1, more delays, and no meaningful drug sales. Chairman and CEO Robert Chioini's optimistic pronouncements and misleading statements should not fool shareholders. In our view, they are nothing more than shallow attempts to mask the company's inaction, continued lack of success, and constantly-delayed timelines for key initiatives...Rockwell's continued poor performance and lack of success is yet further evidence that we need change at Rockwell, and we need it now. It is time for shareholders to tell the company that they will no longer accept the failed execution, extensive delays, underperformance, and disregard for corporate governance that have characterized the company for far too long." The investment advisor and Ravich are asking shareholders to elect Ravich to the company's board.

09:03 EDT Time Inc. sees similar print revenue decline in Q2 vs. Q1 - Sees "significant" cost savings opportunities in 2017.

09:03 EDT T-Mobile announces free upgrade for customers to SyncUP DRIVE - T-Mobile says, "The Un-carrier just gave its customers ANOTHER free upgrade. Starting today, all T-Mobile SyncUP DRIVE customers can now track and manage up to 24 vehicles with a device installed-all in one view from the SyncUP DRIVE app. And all at no extra cost."

09:01 EDT Charles River says continues to look at 'numerous' M&A opportunities

08:46 EDT Time Inc. says 'no scared cows' in asset sale process

08:42 EDT Charles River says China continues to be a growth driver - Says seeing "robust demand" in China.

08:41 EDT Charles River says backs FY17 organic revenue growth of 7%-8.5%

08:39 EDT Cimarex Energy sees Q2 production 1.08-1.113 Bcfe/day

08:37 EDT Charles River says off to 'strong start' to 2017 - Says each client segment delivered higher revenue in Q1. Says continues to be "enthusiastic" about 2017 outlook. Says demand is "robust" and the company continues to gain market share. Comments from Q1 earnings conference call.

08:34 EDT Canadian Pacific intends to launch new share repurchase program - Canadian Pacific announced that the Toronto Stock Exchange has accepted its notice to implement a normal course issuer bid to purchase, for cancellation, up to 4,384,062 common shares or approximately 3% of CP's "public float", as at May 1. The NCIB is scheduled to commence on May 15, 2017 and is due to terminate on May 14, 2018. Purchases of CP common shares under the NCIB may be made through the facilities of the TSX, the NYSE and alternative trading systems. In connection with the NCIB, CP will enter into an automatic purchase plan with its designated broker to allow for purchases of its common shares during internal quarterly blackout periods. As of May 1, CP had 146,747,454 common shares issued and outstanding. CP will not acquire through the facilities of the TSX more than 90,867 common shares during a trading day. In total, CP has repurchased 30.94 million of its common shares since 2014, representing approximately 21% of its public float, as at March 31.

08:31 EDT Canadian Pacific increases quarterly dividend 12.5% to 56.3c per share - Canadian Pacific declared a quarterly dividend of 56.25c per share, an increase of 12.5% to the previous dividend of 50c per share. The dividend is payable on July 31 to holders of record at the close of business on June 30 and is an "eligible" dividend for purposes of the Income Tax Act - Canada - and any similar provincial/territorial legislation.

08:26 EDT Interpace Diagnostics presenting new data on PancraGEN - Interpace Diagnostics announced the data presented in six posters at this week's Digestive Disease Week meeting held May 6th-9th in Chicago. The results presented in three of the posters support the clinical utility of PancraGEN in assessing long-term risk of malignancy in pancreatic cystic lesions and stress the importance of using DNA analysis to better understand risk of cancer in cysts with worrisome imaging or fluid chemistry features that are not definitive for cancer. The results presented in the additional three posters support the clinical utility of PancraGEN as an ancillary test for solid lesions of the pancreas and bile duct using the company's method for testing free-DNA obtained from bile duct brushings and fine needle aspirates. A prospective study of 100 patients reported that ancillary PancraGEN testing enhanced detection of cancer by 30% over the use of only traditional cytology testing alone. A study of 232 patients who had PancraGEN testing as part of their standard of care concluded that the use of PancraGEN as an ancillary test to cytology improves diagnostic accuracy for cancer and impacts physician decision making.

08:23 EDT Argos Therapeutics provides ADAPT trial update after FDA meeting - Argos Therapeutics provided an update on the ADAPT trial, a randomized, active controlled, open-label, multi-center Phase 3 trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma, following a meeting with the FDA. As previously reported, the company has continued to conduct the ADAPT trial notwithstanding the recommendation by the Independent Data Monitoring Committee in February to terminate the trial for futility. In making this determination, Argos considered, among other factors, the degree of maturity of the data set, the mechanism of action of Rocapuldencel-T, which involves the induction of a long-term memory immune response, and the IDMC's assessment of the safety profile of Rocapuldencel-T. Of note, at the time of the IDMC's February interim analysis, the median duration of follow-up was 20 months and more than half the patients in both treatment groups were still alive. The company submitted information related to its analysis of the interim data to the FDA and met with the FDA to discuss the future direction of the ADAPT trial and the Rocapuldencel-T development program. The FDA agreed with the company's plan to continue the trial in accordance with the current protocol to 290 events, the pre-specified number of events at which the analysis of overall survival, the primary endpoint, is to be conducted. The xompany believes that 290 events will have occurred by late 2017 or early 2018. The company also proposed to submit, and the FDA agreed to review, a protocol amendment to increase the pre-specified number of events for the primary analysis of overall survival beyond 290 events, which the company believes could enhance its ability to detect whether Rocapuldencel-T has a delayed treatment effect. The company can extend the study past 290 events without needing to enroll additional patients. As previously reported, the Company has analyzed interim data from a predefined subset of patients who demonstrated an immune response to Rocapuldencel-T at 48 weeks, whose immune response is consistent with the mechanism of action of the therapy and correlates with survival, suggesting that the treatment is biologically active.

08:22 EDT Fate Therapeutics announces FDA clearance of IND application for FATE-NK100 - Fate Therapeutics announced that the U.S. FDA has authorized the company's investigational new drug application for FATE-NK100 in advanced solid tumors. The company plans to promptly initiate the DIMENSION study, an open-label, multi-center, accelerated dose-escalation clinical trial of FATE-NK100 as a monotherapy and in combination with monoclonal antibody therapy in subjects who have failed approved therapies. The Company plans to enroll subjects in the DIMENSION study across three FATE-NK100 treatment arms in an outpatient setting: as monotherapy for solid tumor malignancies, including small cell lung cancer and hepatocellular carcinoma; in combination with trastuzumab for advanced HER2+ cancers, including breast and gastric cancers; and in combination with cetuximab for advanced EGFR1+ cancers, including colorectal and head and neck cancers. Activation of a patient's NK cells has been clinically proven to play a major role in the anti-tumor efficacy of many monoclonal antibodies, including trastuzumab and cetuximab. In preclinical models, FATE-NK100 has been shown to significantly augment antibody-directed cellular cytotoxicity against cancer cells when administered in combination with a monoclonal antibody, including antibodies that target CD20, HER2 and EGFR antigens. Additionally, FATE-NK100 has displayed enhanced anti-tumor activity across a broad range of hematologic and solid tumors, improved persistence and increased resistance to immune checkpoint pathways in preclinical studies compared to NK cell therapies that are being clinically administered today. The primary objective of the DIMENSION study is to evaluate the safety and determine the maximum tolerated dose of a single intravenous infusion of FATE-NK100. Other objectives include determination of objective response rate, time-to-tumor progression, progression-free survival and overall survival. Each of the three arms of the DIMENSION study will enroll in parallel utilizing accelerated dose-escalation, with each arm expected to include an expansion cohort of up to an additional twenty subjects at the maximum tolerated dose level. In addition, observation of a RECIST partial response or greater will enable additional expansion of up to ten subjects in that tumor type.

08:21 EDT Enservco says Ian Dickinson to succeed Rick Kasch as president and CEO - ENSERVCO Corporation announced the appointment of Ian Dickinson as president, CEO and a member of the Board of Directors. Dickinson succeeds Rick Kasch, who is retiring from his positions as president, CEO and board member. Dickinson was previously president and CEO of Premier Oilfield Equipment.

08:18 EDT Inovio announces MedImmune's launch of combination trial for SCCHN - Inovio Pharmaceuticals (INO) announced MedImmune, AstraZeneca's (AZN) global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer T cell responses targeting HPV-associated tumors, and durvalumab, an investigational PD-L1 checkpoint inhibitor. The combination trial will enroll patients with metastatic HPV-associated squamous cell carcinoma of the head & neck with persistent or recurrent disease after chemotherapy treatment. The open-label study is designed to evaluate the safety and efficacy of the combination therapy in approximately 50 subjects at multiple U.S. sites. Subjects will receive multiple doses of MEDI0457 and durvalumab. The primary endpoints of the study are safety and objective response rate. The study will also evaluate immunological impact, progression-free survival and overall survival. Increasing evidence suggests that response rates from checkpoint inhibitors such as MedImmune's durvalumab can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells. Interim data from a MEDI0457 monotherapy study of head and neck cancer patients demonstrated that MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue samples. In 2015, MedImmune acquired exclusive rights to Inovio's INO-3112 immunotherapy for all HPV-associated cancers. MedImmune provided an upfront payment of $27.5M to Inovio as well as potential future payments upon reaching development and commercial milestones totaling up to $700M. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales.

08:15 EDT Motorcar Parts reassigns operational responsibilities - Motorcar Parts announced it has reassigned the responsibilities of the COO position to enhance efficiency, technological innovation and new product line introductions. Steve Kratz, who served as COO, has been appointed to the newly created position of vice president, new technologies. The chief operating officer position will be divided into two categories: under-the-hood and under-the-car product lines. Doug Schooner, currently chief manufacturing officer, will also serve as senior vice president, operations for the under-the-car product lines. Bryan Cain, who most recently served as senior vice president of supply chain, has assumed the position as senior vice president, operations for rotating electrical. In addition to the changes noted above, the company announced the appointment of Jack Vollbrecht as senior vice president, strategy and government relations -- a newly created position. His primary responsibilities include assisting with developing ongoing business strategies and coordinating the company's government affairs outreach activities at the federal, state and local levels; and, identifying proactive legislative opportunities and related activities to support the company's business interests within the automotive aftermarket sector.

08:13 EDT Savara announces expedited U.S. Molgradex development strategy - Savara announced that it has received guidance from the U.S. FDA on the clinical program requirements for a New Drug Application submission in the U.S. for Molgradex, an inhaled formulation of recombinant human GM-CSF, for the treatment of autoimmune pulmonary alveolar proteinosis, or PAP. Based on the FDA's guidance, Savara will modify the endpoint hierarchy and statistical analyses of its ongoing IMPALA study, currently enrolling patients in Europe and Japan, to qualify the study as a pivotal Phase 3 study in the U.S. The total number of patients to be enrolled will be increased from 51 to 90 to support the modified design. If successful, the amended study would serve as the sole pivotal study for regulatory submission for marketing authorization of Molgradex for the treatment of PAP in the U.S. in addition to Europe and Japan.

08:10 EDT Veracyte's genomic classifiers featured in six studies at ATS conference - Veracyte announced that data from multiple studies supporting use of the company's genomic classifiers to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis will be presented at the American Thoracic Society 2017 International Conference being held May 19-24 in Washington, DC. Two abstracts accepted for poster presentation at the conference will highlight data from studies supporting the clinical utility of the Percepta Bronchial Genomic Classifier. The Percepta classifier is used to improve the safety and accuracy of lung cancer screening and diagnosis by resolving inconclusive bronchoscopy results in patients undergoing evaluation for suspicious lung nodules or lesions. Four additional abstracts will feature data demonstrating the clinical performance and utility of the Envisia Genomic Classifier, as well as the clinical need for the genomic test to resolve the significant challenges associated with IPF diagnosis. Veracyte launched the Envisia classifier, which is designed to improve the diagnosis of IPF without the need for risky, costly invasive procedures, during late 2016.

08:10 EDT Legg Mason reports preliminary AUM approximately $731B as of April 30 - This month's AUM included long-term outflows of $1.5B, consisting of net outflows in fixed income of $1B and equities of $0.6B, partially offset by alternatives inflows of $0.1B. Liquidity outflows were $0.2B and this month's AUM included a negative foreign exchange impact of $0.1B.

08:08 EDT Nuance enters strategic partnership with Lexmark - Nuance announced a new strategic partnership for Lexmark, a global imaging solutions leader, to provide Nuance document imaging solutions worldwide. Specifically, the relationship includes rights for Lexmark to sell and distribute Nuance AutoStore, Equitrac Office/Express and SafeCom. In addition, Nuance will provide service and support to qualifying customers. For Lexmark, partnering with Nuance reinforces its commitment to providing world-class enterprise-ready workflow solutions that enable organizations to increase productivity and enhance document security.

08:04 EDT Atossa receives second positive safety committee decision in tamoxifen study - Atossa Genetics announced that it has received the second positive interim review on its Phase 1 study of endoxifen, which is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high risk patients. The Independent Safety Committee reviewed the blinded data generated from the second cohort of the study and concluded that the study may advance to the final topical dosing level.

08:02 EDT AeroVironment begins full rate production, shipment of Mantis i45 sensor suite - AeroVironment announced that its Mantis i45 electro-optical/infrared gimbal sensor suite designed for the AeroVironment Puma AE small UAS is now in full production and shipping to customers. Unveiled last May, the i45 Mantis significantly enhances Puma AE's intelligence, surveillance and reconnaissance capabilities.

08:01 EDT JetBlue reports April traffic up 8.2% y/y, capacity up 6.6% - JetBlue Airways reported its preliminary traffic results for April 2017. Traffic in April increased 8.2% from April 2016, on a capacity increase of 6.6%. Load factor for April 2017 was 85.3%, an increase of 1.2 points from April 2016. JetBlue's preliminary completion factor was 98.5% and its on-time performance was 72.4%.

08:01 EDT AllianceBernstein reports AUM $504B at April 30 - AllianceBernstein reported preliminary assets under management increased to $504B during April from $498B at the end of March. The 1.2% increase was the result of market appreciation and slightly positive firmwide net flows. By channel, Retail net inflows were partially offset by net outflows from Institutions and Private Wealth Management.

07:57 EDT Coty up 9% to $19.50 after Q3 results beat estimates

07:39 EDT Proteon Therapeutics vonapanitase receives FDA breakthrough therapy designation - Proteon Therapeutics announced that its investigational treatment, vonapanitase, has received Breakthrough Therapy designation from the FDA for increasing arteriovenous fistula secondary patency and use for hemodialysis in patients on or expected to initiate hemodialysis. Secondary patency and fistula use for hemodialysis are the co-primary endpoints of Proteon's ongoing pivotal Phase 3 clinical trial, PATENCY-2. As previously announced, the FDA has confirmed that the PATENCY-2 trial together with data from previously completed studies would provide the basis for a Biologics License Application, or BLA, submission as a single pivotal study if PATENCY-2 is successful in showing statistical significance on each of the co-primary endpoints.

07:37 EDT Wendy's backs 2020 goals - Wendy's continues to expect to achieve the following goals by the end of 2020: global systemwide sales in constant currency and excluding Venezuela of $12B; global restaurant count of 7,500; global Image Activation of at least 70%; adjusted EBITDA margin of 38%-405; free cash flow of $275M, Capital Expenditures of $65M.

07:35 EDT Adaptimmune initiates AFP SPEAR T-cell study - Adaptimmune Therapeutics announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular carcinoma, the sixth most common cancer worldwide. This study is now open for enrollment. This is Adaptimmune's second wholly-owned therapeutic candidate to enter clinical trials. The company already has ongoing studies to evaluate its T-cell therapy targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers.

07:32 EDT SunOpta targets implementation of $30M of annualized enhancements of EBITDA - As previously announced, SunOpta, with the assistance of Oaktree, is conducting a thorough review of the Company's operations, management and governance, with the objective of maximizing the Company's ability to deliver long-term value to its shareholders. Through this review, management and the Board have developed a Value Creation Plan built on four pillars: portfolio optimization, operational excellence, go-to-market effectiveness and process sustainability. As part of the first phase of the Value Creation Plan, the Company is targeting implementation of $30 million of productivity-driven annualized enhancements of EBITDA, to be implemented over 2017 and 2018. In the near-term, these benefits are expected to be offset by structural investments made in the areas of quality, sales, marketing, operations and engineering resources. Additionally, the Company is incurring non-structural third-party consulting support, severance, and recruiting costs. The plan also calls for increased investment in capital upgrades at several manufacturing facilities to enhance food safety and manufacturing efficiencies. Over time, these investments are expected to yield additional improvement in EBITDA beyond the $30 million of initial productivity-driven savings. Since the initiation of the Value Creation Plan, the Company has implemented process improvements and cost savings expected to yield $1.3 million of annualized EBITDA benefits.

07:31 EDT Mylan says not providing forward looking guidance - Mylan is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures.

07:19 EDT Tribune Media interim CEO says Q1 results 'in line with our expectations' - "We are pleased and excited with Monday's announcement that Tribune Media has agreed to be acquired by Sinclair Broadcast Group, marking the culmination of a thorough strategic review which focused on optimizing shareholder value," said Peter Kern, Tribune Media's interim CEO. "As for the first quarter, our financial results were in line with our expectations, with anticipated reductions in political advertising and real estate revenues, and increased programming expenses due to airing more hours of originals at WGN America. We expect the next three quarters will be strong as we cycle past core advertising displacement, realize significant acceleration of retransmission revenues, and continue disciplined expense management across the company. We are reaffirming our full year financial guidance for 2017 and are intensely focused on completing our transaction with Sinclair."

07:11 EDT Garmin announces Dash Cam 65W - Garmin International announced the Dash Cam 65W, its newest dash cam model capable of capturing an exceptional 180-wide-angle field of view to expand the scope of its high-quality 1080p video recording capability.

07:10 EDT Vericel receives FDA RMAT designation for ixmyelocel-T - Vericel announced that the FDA has granted the Regenerative Medicine Advanced Therapy, or RMAT, designation for ixmyelocel-T, an investigational product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy. The RMAT designation is a new expedited program established under the 21st Century Cures Act to foster the development and approval of regenerative medicine products intended for the treatment of serious diseases and conditions.

07:09 EDT CECO Environmental reports total backlog of $184.2M at March 31 - As compared with $197M on December 31, 2016, and $228.1M on March 31, 2016.

07:01 EDT Enviva sees FY17 net income $29M-$33M - Sees FY17 adjusted EBITDA $111M-$115M. Sees FY17 CapEx $5.1M. In FY17 expect to distribute at least $2.36 per common and subordinated unit.

06:52 EDT Wabtec appoints Stephane Rambaud-Measson as COO - Wabtec has named Stephane Rambaud-Measson executive vice president and COO and elected him as a member of the company's board. The company has also elected Albert J. Neupaver as chairman of the company's board of directors. Raymond T. Betler remains president and CEO and a board member. Rambaud-Measson had served as Faiveley Transport's CEO and chairman of its Management Board before joining Wabtec as president and CEO of the Transit Group when Wabtec acquired Faiveley in December 2016. He will remain CEO and chairman of Faiveley Transport and will continue to report to Betler. Before joining Wabtec, Rambaud-Measson joined Faiveley as executive VP in March 2014. Previously, he was CEO of Veolia Verkehr.

06:49 EDT Wabtec raises quarterly dividend 20% to 12c per share - Wabtec increased its regular quarterly dividend by 20% to 12c per share from 10c per share. The new dividend rate will be payable initially Aug. 28 to shareholders of record Aug. 14.

06:40 EDT Coty CEO says 'fiscal 2017 is a transitional year' - Commenting on Q3 financial results and strategic outlook, Camillo Pane, Coty CEO said: "Q3 was a better quarter. The underlying net revenue trend, excluding the contributions from ghd, Younique and one month of the Brazil Acquisition, improved sequentially to -2% at constant currency compared to a high single digit decline in the first half. This improvement was driven by good growth performance in the Luxury division, flat performance in Professional Beauty, and some improvement but continued negative performance in the Consumer Beauty division. Equally encouraging was the performance of our acquired businesses of the Brazil acquisition, Younique and ghd. These three businesses combined showed strong performance year over year, outperforming their respective markets and are expected to materially strengthen the growth profile of the total company. As to profits, our Q3 performance was very solid, with our adjusted operating income more than doubling in Q3 versus the prior year period, underlining the margin strength of our business. It is clear that fiscal 2017 is a transitional year and the path to recovery will take some time and will not be a straight line. For example, we expect the constant currency net revenue trends in Q4 excluding Younique and ghd to weaken sequentially versus Q3. In Q3, we continued to execute on the strategy I outlined last quarter to position Coty to become a challenger and leader in beauty, and drive sustained profitable growth over time. We aim to achieve these strategic objectives through four key pillars, specifically the repositioning some of the brands, making significant changes to our innovation and product development process, accelerating our end-to-end digital transformation including e-commerce, and revamping our in-store execution. I am pleased with the progress made in the quarter on the four pillars, especially on the announced partnerships with new creative agencies and the implementation of changes to our innovation process. On the integration of the P&G Beauty Business, we are making good progress and we just exited the Transitional Services Agreement in North America on May 1, which is a significant milestone in this journey. Regarding acquisitions, the recently announced agreement to acquire the long term exclusive license of the Burberry Beauty business should further strengthen our Luxury portfolio of brands without a material impact to our leverage ratio, highlighting our disciplined approach to valuation, and maintaining a strong balance sheet. In sum, I am confident that the strategies and action plans we are deploying throughout the organization are setting the stage to realize the enormous potential of Coty as a global leader and challenger in beauty."

06:21 EDT YY appoints Bing Jin as CFO - YY has appointed Bing Jin as CFO effectively immediately. Jin succeeds Eric He, who has decided to retire after serving as CFO since August 2011. Prior to joining YY, Mr. Jin served as the Head of China Technology of Investment Banking and Capital Markets, Asia Pacific, at Credit Suisse.

06:19 EDT Sand Grove reports 5.2% stake in Syneron Medical - Sand Grove Capital Management reports a 1.82M share position in Syneron Medical, which represents 5.2% of the outstanding shares. The filing with the SEC allows for activism.

06:15 EDT AXA announces intention to IPO U.S. operations - AXA announces its intention to IPO its US operations. AXA says the strategic decision will create significant additional financial flexibility to accelerate AXA's transformation, in line with Ambition 2020 objectives. AXA intends to list a minority stake of AXA's US operations -- expected to consist of its US Life & Savings business and AXA Group's interest in AB -- in 1H18, subject to market conditions. To enhance the capitalization of the US operations ahead of the IPO, about USD 1.0 billion of outstanding debt owed by AXA US to AXA Group will be converted into equity. The proceeds of the transaction would be reinvested in the Group's priority lines of business, including Health, Capital-light Savings, Protection and P&C commercial lines, in line with the Ambition 2020 strategy, and/or potentially returned to shareholders depending on acquisition opportunities and market conditions. The AXA Group reaffirms the following key financial objectives for 2015-2020: Underlying earnings per share CAGR of 3%-7%, Solvency II ratio target range of 170%-230%, cumulative cash remitted to Group holding company of Euro 24-27 billion, and adjusted Return on Equity of 12%-14%.

06:11 EDT Time Inc. says no longer providing annual revenue outlook - Management said, "Time Inc. is a company undergoing rapid transformation. For this reason, it is important to focus on longer-term targets and performance. Given this longer-term perspective, the variability of our advertising revenues, and the potential impacts from portfolio rationalization, the Company is modifying its financial guidance approach similar to many other companies in the media sector. Beginning with this earnings release, the Company no longer intends to provide quarterly pacing or an annual revenue outlook. We will continue to offer quarterly insights and key metrics as appropriate. We will also provide our annual outlook for Adjusted OIBDA. The content of our quarterly insights and key metrics may vary quarter-to-quarter depending on what we consider to be relevant at the time."

06:09 EDT ChemChina says about 82% of Syngenta shares tendered in offer - ChemChina announced the definitive interim results for the tender offers to purchase all publicly held registered shares of Syngenta and all outstanding American Depositary Shares representing Common Shares. At the end of the Main Offer Period on May 4, 4:00 p.m. CEST, around 82.2% of Common Shares have been validly tendered in, and not withdrawn from, the offers. The Minimum Acceptance Rate condition of 67% of issued Syngenta shares has been satisfied and the offers have been successful. An additional acceptance period will begin on May 11, 2017. Shareholders of Syngenta and holders of ADSs who have not tendered their Common Shares or ADSs into the offers during the main offer period may accept the offers during the additional acceptance period, in which case they will receive the offer price in the second settlement. Such shareholders and holders of ADSs are advised that the additional acceptance period will end on May 24, 2017, 4:00 p.m. CEST / 10:00 a.m. New York City Time.

06:07 EDT Syneron Medical announces end of go-shop period - Syneron Medical announced the expiration of the 37-day "go-shop" period under the terms of the previously announced merger agreement, which was entered into on April 2, 2017, pursuant to which Syneron Candela will be acquired by an affiliate of funds advised by Apax Partners. Under the Merger Agreement, Syneron Candela and its representatives were permitted to solicit and engage in negotiations with respect to alternative acquisition proposals until 11:59 p.m. on May 9, 2017. During the "go-shop" period, Syneron Candela, with the assistance of Barclays, engaged in an active and extensive solicitation of 59 potential bidders, both strategic and financial, which resulted in two potential bidders each negotiating and entering into a confidentiality agreement with Syneron Candela. Syneron Candela did not receive any alternative acquisition proposals during the "go-shop" period, including from the two parties who entered into confidentiality agreements and subsequently confirmed they were not interested in pursuing an acquisition of Syneron Candela. Beginning at 12:00 a.m., Israeli Time, on May 10, 2017, Syneron Candela became subject to customary "no-shop" provisions that limit its and its representatives' ability to solicit alternative acquisition proposals from third parties or to provide confidential information to third parties, subject to customary "fiduciary out" provisions. The acquisition is expected to be completed during the third quarter.

06:06 EDT OncoSec enters clinical collaboration, supply agreement with Merck - OncoSec (ONCS) has entered a clinical trial collaboration and supply agreement with Merck (MRK) to evaluate the combination of OncoSec's ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA in a Phase II clinical trial, referred to as PISCES. The planned clinical trial will evaluate the safety and efficacy of the combination in patients with metastatic melanoma following disease progression on previous treatment with an anti-PD-1 therapy. Eligible patients for this Phase II study will be those with Stage III/IV metastatic melanoma who are progressing, or have progressed, on previous treatment with an anti-PD-1 therapy. The collaboration agreement is between OncoSec Medical Incorporated and Merck, through a subsidiary. Under the agreement, OncoSec will sponsor and fund the study and Merck will provide KEYTRUDA. Additional details of the collaboration were not disclosed.

06:02 EDT SiteOne Landscape still sees FY17 adjusted EBITDA $155M-$165M

05:59 EDT European Commission to launch competition probe in ecommerce sector - The European Commission's final report on the e-commerce sector inquiry identifies business practices that may restrict competition. It allows the Commission to target its enforcement of EU antitrust rules in e-commerce markets and has already prompted companies to review their practices. Commissioner Margrethe Vestager in charge of competition policy said: "Certain practices by companies in e-commerce markets may restrict competition by unduly limiting how products are distributed throughout the EU. Our report confirms that. These restrictions could limit consumer choice and prevent lower prices online. At the same time, we find that there is a need to balance the interests of both online and 'brick-and-mortar' retailers. All to the benefit of consumers. Our findings help us to target the enforcement of EU competition rules in e-commerce markets".

05:52 EDT Elbit Systems awarded $40M contract by Brazilian Marine Corps - Elbit Systems announced that it was awarded a contract from the Brazilian Marine Corps, or BMC, for the supply of advanced C4ISR, Electronic Warfare, or EW, radio and communication systems. The contract, in an amount, of approximately $40M, will be performed over a two-year period. The contract calls for the supply of cutting-edge technologies and operational capabilities, including a variety of Battle Management Systems, or BMS, applications, C4I systems for artillery, latest generation of Soldier C4I suit as well as advanced EW capabilities. The systems will be deployed in fixed and deployed command centers and in vehicles/APCs and dismounted configurations, aiming to significantly enhance Marine Forces' operational effectiveness, and aligning the BMC with the most modern Network Centric Warfare concept.

05:34 EDT Allergan CEO: Q1 is lowest sales quarter - Says higher royalty products selling faster. Says aesthetics very strong in Q1. Says people are aware of company's products, but penetration is quite small. Brent Saunders is speaking on CNBC.